NCT03410108 2024-05-08Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)TakedaPhase 2 Completed104 enrolled 22 charts